Experimental cancer drug trial halted early – what we know

NCT ID NCT04240704

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tested a new drug called JBH492 in 25 people with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The main goal was to check safety and find the right dose. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Helsinki, FIN-00029, Finland

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

Conditions

Explore the condition pages connected to this study.